The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms

Aims:  Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods:  The subjects were 29 ou...

Full description

Saved in:
Bibliographic Details
Published inPsychiatry and clinical neurosciences Vol. 66; no. 2; pp. 146 - 152
Main Authors Suzuki, Hidenobu, Gen, Keishi
Format Journal Article
LanguageEnglish
Published Melbourne, Australia Blackwell Publishing Asia 01.03.2012
Wiley-Blackwell
Subjects
Online AccessGet full text
ISSN1323-1316
1440-1819
DOI10.1111/j.1440-1819.2011.02311.x

Cover

Abstract Aims:  Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods:  The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug‐Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti‐D2 and anti‐5‐HT2A activities were measured by [3H]‐spiperone and [3H]‐ketanserin radioreceptor assays. Results:  The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (P < 0.05). A negative correlative tendency was found between the S/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S/D ratios were divided into a low S/D ratio group and a high S/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration‐low S/D ratio group was significantly higher than in the high plasma concentration‐high S/D ratio, low plasma concentration‐high S/D ratio and low plasma concentration‐low S/D ratio groups (P < 0.05 for all). Conclusions:  These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti‐5HT2A activity is predominant over anti‐D2 activity.
AbstractList Aims: Blonanserin is a second-generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti-5-HT2A activity/anti-D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods: The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti-D2 and anti-5-HT2A activities were measured by [3H]-spiperone and [3H]-ketanserin radioreceptor assays. Results: The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (P<0.05). A negative correlative tendency was found between the S/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S/D ratios were divided into a low S/D ratio group and a high S/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration-low S/D ratio group was significantly higher than in the high plasma concentration-high S/D ratio, low plasma concentration-high S/D ratio and low plasma concentration-low S/D ratio groups (P<0.05 for all). Conclusions: These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti-5HT2A activity is predominant over anti-D2 activity.
Aims:  Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma anti‐5‐HT2A activity/anti‐D2 activity (S/D) ratio and extrapyramidal symptoms (EPS) in blonanserin dosing. Methods:  The subjects were 29 outpatients with schizophrenia. We assessed EPS using the Drug‐Induced Extrapyramidal Symptoms Scale (DIEPSS). The plasma concentrations were measured by high performance liquid chromatography, and the plasma anti‐D2 and anti‐5‐HT2A activities were measured by [3H]‐spiperone and [3H]‐ketanserin radioreceptor assays. Results:  The results revealed that there were significant correlations between both the plasma concentration and the DIEPSS total score (P < 0.05). A negative correlative tendency was found between the S/D ratio and the DIEPSS total score. Furthermore, the plasma concentrations were divided into a low plasma concentration group and a high plasma concentration group, and the S/D ratios were divided into a low S/D ratio group and a high S/D ratio group. We then compared each group based on the DIEPSS total scores. The score in the high plasma concentration‐low S/D ratio group was significantly higher than in the high plasma concentration‐high S/D ratio, low plasma concentration‐high S/D ratio and low plasma concentration‐low S/D ratio groups (P < 0.05 for all). Conclusions:  These findings indicate that the incidence of EPS during treatment with blonanserin is mainly determined by plasma concentration, but the incidence of EPS may be inhibited when anti‐5HT2A activity is predominant over anti‐D2 activity.
Author Suzuki, Hidenobu
Gen, Keishi
Author_xml – sequence: 1
  givenname: Hidenobu
  surname: Suzuki
  fullname: Suzuki, Hidenobu
  email: suzuhide@red.livedoor.com
  organization: Department of Psychiatry, Tanzawa Hospital, Hadano
– sequence: 2
  givenname: Keishi
  surname: Gen
  fullname: Gen, Keishi
  organization: Department of Psychiatry, Seimo Hospital, Gunma, Japan
BackLink http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=25550300$$DView record in Pascal Francis
BookMark eNo9kctO3DAUhqOKSgXad_AGqYtm8CUeJ4su0LRAK0Rvg1haTnwCniZ2sD1l8mZ9vDoZOl7YR_q-_3jxn2RH1lnIMkTwgqRzvlmQosA5KUm1oJiQBaYs3btX2fEBHKWZUZYTRpZvspMQNhhjxpbkOPu7fgTkoVPROBsezYBqiM8AFsUEhk6FXqHG2QZs9LOEXIvqzlllA3hjPyBlNTIx_JeVjSZPyEVnjUU8v17TC6SaaP6YOJ7PWLtB9cYC-kQPBM3r523abx9yY_W2AY1glz4eRp8CWnUojP0QXR_eZq9b1QV49_KeZneXn9er6_zm29WX1cVNbuiyIDkTTLGyqbAgXHFMgQncMiCsqSmmtW41bQUnglZaVBQzVdKSa0p1UXFRQ8lOs_f7vYN3T1sIUfYmNNB1yoLbBkkwLTHDhJOknr2oKjSqa72yjQly8KZXfpSUc55MnLyPe-_ZdDAeOMFyalRu5FScnIqTU6NyblTu5PfV7TSlfL7PmxBhd8gr_1suBRNc3t9eSYF_8J-XxS_5lf0DqnSqJQ
ContentType Journal Article
Copyright 2012 The Authors. Psychiatry and Clinical Neurosciences © 2012 Japanese Society of Psychiatry and Neurology
2015 INIST-CNRS
Copyright_xml – notice: 2012 The Authors. Psychiatry and Clinical Neurosciences © 2012 Japanese Society of Psychiatry and Neurology
– notice: 2015 INIST-CNRS
DBID BSCLL
IQODW
7TK
DOI 10.1111/j.1440-1819.2011.02311.x
DatabaseName Istex
Pascal-Francis
Neurosciences Abstracts
DatabaseTitle Neurosciences Abstracts
DatabaseTitleList Neurosciences Abstracts

DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1440-1819
EndPage 152
ExternalDocumentID 25550300
PCN2311
ark_67375_WNG_70Q5RF4S_J
Genre article
GroupedDBID ---
.3N
.55
.GA
.Y3
05W
0R~
10A
123
1OB
1OC
24P
29P
31~
33P
36B
3O-
3SF
4.4
50Y
50Z
51W
51X
52M
52N
52O
52P
52R
52S
52T
52U
52V
52W
52X
53G
5HH
5LA
5VS
66C
7.U
702
7PT
8-0
8-1
8-3
8-4
8-5
8UM
930
A01
A03
AAESR
AAEVG
AAHHS
AANLZ
AAONW
AASGY
AAXRX
AAZKR
ABCQN
ABCUV
ABDBF
ABEML
ABIVO
ABJNI
ABPVW
ABQWH
ABXGK
ACAHQ
ACBWZ
ACCFJ
ACCZN
ACGFS
ACGOF
ACMXC
ACPOU
ACPRK
ACSCC
ACXBN
ACXQS
ADBBV
ADBTR
ADEOM
ADIZJ
ADKYN
ADMGS
ADOZA
ADXAS
ADZMN
AEEZP
AEIGN
AEIMD
AENEX
AEQDE
AEUQT
AEUYR
AFBPY
AFEBI
AFFPM
AFGKR
AFPWT
AFZJQ
AHBTC
AHEFC
AHMBA
AIACR
AITYG
AIURR
AIWBW
AJBDE
ALAGY
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMBMR
AMYDB
ATUGU
AZBYB
AZFZN
AZVAB
BAFTC
BAWUL
BDRZF
BFHJK
BHBCM
BMXJE
BROTX
BRXPI
BSCLL
BY8
C45
CAG
COF
CS3
D-6
D-7
D-E
D-F
DCZOG
DIK
DPXWK
DR2
DRFUL
DRMAN
DRSTM
DU5
DUUFO
E3Z
EAD
EAP
EBC
EBD
EBS
EJD
EMB
EMK
EMOBN
EPS
ESX
EX3
F00
F01
F04
F5P
FEDTE
FUBAC
G-S
G.N
GODZA
H.X
HF~
HGLYW
HVGLF
HZI
HZ~
IHE
IX1
J0M
K48
KBYEO
LATKE
LC2
LC3
LEEKS
LH4
LITHE
LOXES
LP6
LP7
LUTES
LW6
LYRES
MEWTI
MK4
MRFUL
MRMAN
MRSTM
MSFUL
MSMAN
MSSTM
MXFUL
MXMAN
MXSTM
N04
N05
N9A
NF~
O66
O9-
OIG
OK1
OVD
P2P
P2W
P2X
P2Z
P4B
P4D
PALCI
PQQKQ
Q.N
Q11
QB0
R.K
RIWAO
RJQFR
ROL
RX1
SAMSI
SUPJJ
SV3
TEORI
TKC
TR2
TUS
UB1
W8V
W99
WBKPD
WHWMO
WIH
WIJ
WIK
WIN
WOHZO
WOW
WQJ
WRC
WUP
WVDHM
WXI
WXSBR
X7M
XG1
YFH
ZXP
ZZTAW
~02
~IA
~WT
AAHQN
AAIPD
AAMNL
AANHP
AAYCA
ACRPL
ACUHS
ACYXJ
ADNMO
AFWVQ
ALVPJ
AAPBV
AAUGY
AAVGM
ABHUG
ABPTK
ACXME
ADAWD
ADDAD
AFVGU
AGJLS
IQODW
7TK
AAMMB
AEFGJ
AEYWJ
AGQPQ
AGXDD
AGYGG
AIDQK
AIDYY
ID FETCH-LOGICAL-i2641-373a38c90715a502e370f3e13cb202bdfd2f751729d79203a8285d22d4957be83
IEDL.DBID DR2
ISSN 1323-1316
IngestDate Tue Aug 05 10:20:19 EDT 2025
Sun Oct 22 16:10:05 EDT 2023
Wed Jan 22 17:10:13 EST 2025
Wed Oct 30 09:50:50 EDT 2024
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords Nervous system diseases
Dopamine
Serotonin
Neuroleptic
Psychotropic
Toxicity
drug-induced extrapyramidal symptoms
activity/antidopamine D
Catecholamine
activity ratio
plasma concentration
Cerebral disorder
Symptomatology
Central nervous system disease
Neurotransmitter
Anti-serotonin 5-HT
Blonanserin
DIEPSS
Extrapyramidal syndrome
Language English
License CC BY 4.0
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-i2641-373a38c90715a502e370f3e13cb202bdfd2f751729d79203a8285d22d4957be83
Notes ark:/67375/WNG-70Q5RF4S-J
ArticleID:PCN2311
istex:845DC69114E9F688EBDDB7D12535D677B5336C01
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
PQID 1028030151
PQPubID 23462
PageCount 7
ParticipantIDs proquest_miscellaneous_1028030151
pascalfrancis_primary_25550300
wiley_primary_10_1111_j_1440_1819_2011_02311_x_PCN2311
istex_primary_ark_67375_WNG_70Q5RF4S_J
PublicationCentury 2000
PublicationDate March 2012
PublicationDateYYYYMMDD 2012-03-01
PublicationDate_xml – month: 03
  year: 2012
  text: March 2012
PublicationDecade 2010
PublicationPlace Melbourne, Australia
PublicationPlace_xml – name: Melbourne, Australia
– name: Richmond
PublicationTitle Psychiatry and clinical neurosciences
PublicationYear 2012
Publisher Blackwell Publishing Asia
Wiley-Blackwell
Publisher_xml – name: Blackwell Publishing Asia
– name: Wiley-Blackwell
References Ochi T, Sakamoto M, Minamida A et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg. Med. Chem. Lett. 2005; 15: 1055-1059.
Ishigooka J. An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D2 and serotonin 5-HT2A antagonism. Jpn. J. Clin. Psychopharmacol. 2008; 11: 817-833 (in Japanese).
Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic durgs on the basis of dopamine D-1, D-2 and serotonin 2 pki values. J. Pharmacol. Exp. Ther. 1989; 251: 238-246.
Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 1159-1172.
Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625.
Murasaki M. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with haloperidol. Jpn. J. Clin. Psychopharmacol. 2007; 10: 2059-2079 (in Japanese).
Murasaki M. Preclinical and clinical features of blonanserin. Jpn. J. Clin. Psychopharmacol. 2008; 11: 855-868 (in Japanese).
Yang J, Bahk WM, Cho HS et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175.
Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. Hum. Psychopharmacol. 2010; 25: 342-346.
Oka M, Noda Y, Ochi Y et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther. 1993; 264: 158-165.
Yanagida H, Morokawa Y. A study of risperidone induced extrapyramidal symptoms- Plasma Risperidone, 9-OH Risperidone concentration and plasma anti 5-HT2A activity/anti-D2 activity. Jpn. J. Clin. Psychopharmacol. 2001; 4: 241-249 (in Japanese).
Ohoyama K, Yamamura S, Hamaguchi T et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011; 653: 47-57.
Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 1991; 43: 587-604.
2009; 23
2010; 33
2011; 653
2010; 25
1991; 43
2001; 4
1989; 251
1996
2003; 27
2008; 11
2005; 15
2007; 10
1993; 264
References_xml – reference: Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotonin receptors: Their key role in drugs to treat schizophrenia. Prog. Neuropsychopharmacol. Biol. Psychiatry 2003; 27: 1159-1172.
– reference: Ishigooka J. An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D2 and serotonin 5-HT2A antagonism. Jpn. J. Clin. Psychopharmacol. 2008; 11: 817-833 (in Japanese).
– reference: Yang J, Bahk WM, Cho HS et al. Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double-blind, risperidone-compared trial. Clin. Neuropharmacol. 2010; 33: 169-175.
– reference: Ochi T, Sakamoto M, Minamida A et al. Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD-5423, a novel antipsychotic agent. Bioorg. Med. Chem. Lett. 2005; 15: 1055-1059.
– reference: Oka M, Noda Y, Ochi Y et al. Pharmacological profile of AD-5423, a novel antipsychotic with both potent dopamine-D2 and serotonin-S2 antagonist properties. J. Pharmacol. Exp. Ther. 1993; 264: 158-165.
– reference: Murasaki M. Preclinical and clinical features of blonanserin. Jpn. J. Clin. Psychopharmacol. 2008; 11: 855-868 (in Japanese).
– reference: Meltzer HY, Nash JF. Effects of antipsychotic drugs on serotonin receptors. Pharmacol. Rev. 1991; 43: 587-604.
– reference: Yanagida H, Morokawa Y. A study of risperidone induced extrapyramidal symptoms- Plasma Risperidone, 9-OH Risperidone concentration and plasma anti 5-HT2A activity/anti-D2 activity. Jpn. J. Clin. Psychopharmacol. 2001; 4: 241-249 (in Japanese).
– reference: Murasaki M. Clinical evaluation of blonanserin for schizophrenia-A randomized controlled study comparing blonanserin with haloperidol. Jpn. J. Clin. Psychopharmacol. 2007; 10: 2059-2079 (in Japanese).
– reference: Garcia E, Robert M, Peris F, Nakamura H, Sato N, Terazawa Y. The efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: A randomized, double-blind, placebo-controlled, multicentre study. CNS Drugs 2009; 23: 615-625.
– reference: Meltzer HY, Matsubara S, Lee JC. Classification of typical and atypical antipsychotic durgs on the basis of dopamine D-1, D-2 and serotonin 2 pki values. J. Pharmacol. Exp. Ther. 1989; 251: 238-246.
– reference: Ohoyama K, Yamamura S, Hamaguchi T et al. Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex. Eur. J. Pharmacol. 2011; 653: 47-57.
– reference: Suzuki H, Gen K. The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti-dopamine D2 and anti-serotonin 5-HT2A activity. Hum. Psychopharmacol. 2010; 25: 342-346.
– volume: 15
  start-page: 1055
  year: 2005
  end-page: 1059
  article-title: Syntheses and properties of the major hydroxy metabolites in humans of blonanserin AD‐5423, a novel antipsychotic agent
  publication-title: Bioorg. Med. Chem. Lett.
– volume: 25
  start-page: 342
  year: 2010
  end-page: 346
  article-title: The relationship between the daily dose, the plasma concentration of blonanserin, and its plasma anti‐dopamine D and anti‐serotonin 5‐HT activity
  publication-title: Hum. Psychopharmacol.
– volume: 10
  start-page: 2059
  year: 2007
  end-page: 2079
  article-title: Clinical evaluation of blonanserin for schizophrenia‐A randomized controlled study comparing blonanserin with haloperidol
  publication-title: Jpn. J. Clin. Psychopharmacol.
– volume: 264
  start-page: 158
  year: 1993
  end-page: 165
  article-title: Pharmacological profile of AD‐5423, a novel antipsychotic with both potent dopamine‐D2 and serotonin‐S2 antagonist properties
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 23
  start-page: 615
  year: 2009
  end-page: 625
  article-title: The efficacy and safety of blonanserin compared with haloperidol in acute‐phase schizophrenia: A randomized, double‐blind, placebo‐controlled, multicentre study
  publication-title: CNS Drugs
– volume: 251
  start-page: 238
  year: 1989
  end-page: 246
  article-title: Classification of typical and atypical antipsychotic durgs on the basis of dopamine D‐1, D‐2 and serotonin 2 pki values
  publication-title: J. Pharmacol. Exp. Ther.
– volume: 33
  start-page: 169
  year: 2010
  end-page: 175
  article-title: Efficacy and tolerability of blonanserin in the patients with schizophrenia: A randomized, double‐blind, risperidone‐compared trial
  publication-title: Clin. Neuropharmacol.
– volume: 11
  start-page: 855
  year: 2008
  end-page: 868
  article-title: Preclinical and clinical features of blonanserin
  publication-title: Jpn. J. Clin. Psychopharmacol.
– year: 1996
– volume: 4
  start-page: 241
  year: 2001
  end-page: 249
  article-title: A study of risperidone induced extrapyramidal symptoms‐ Plasma Risperidone, 9‐OH Risperidone concentration and plasma anti 5‐HT activity/anti‐D activity
  publication-title: Jpn. J. Clin. Psychopharmacol.
– volume: 43
  start-page: 587
  year: 1991
  end-page: 604
  article-title: Effects of antipsychotic drugs on serotonin receptors
  publication-title: Pharmacol. Rev.
– volume: 653
  start-page: 47
  year: 2011
  end-page: 57
  article-title: Effect of novel atypical antipsychotic, blonanserin, on extracellular neurotransmitter level in rat prefrontal cortex
  publication-title: Eur. J. Pharmacol.
– volume: 11
  start-page: 817
  year: 2008
  end-page: 833
  article-title: An overview of clinical trials of blonanserin, a new antipsychotic drug with dopamine D and serotonin 5‐HT antagonism
  publication-title: Jpn. J. Clin. Psychopharmacol.
– start-page: 11
  year: 1996
  end-page: 60
– volume: 27
  start-page: 1159
  year: 2003
  end-page: 1172
  article-title: Serotonin receptors: Their key role in drugs to treat schizophrenia
  publication-title: Prog. Neuropsychopharmacol. Biol. Psychiatry
SSID ssj0003361
Score 1.9944851
Snippet Aims:  Blonanserin is a second‐generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma...
Aims: Blonanserin is a second-generation antipsychotic that was developed in Japan. We investigated the relationships between plasma concentration, the plasma...
SourceID proquest
pascalfrancis
wiley
istex
SourceType Aggregation Database
Index Database
Publisher
StartPage 146
SubjectTerms Anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio
Biological and medical sciences
blonanserin
DIEPSS
drug-induced extrapyramidal symptoms
Extrapyramidal system
High-performance liquid chromatography
Medical sciences
Mental disorders
Nervous system (semeiology, syndromes)
Nervous system as a whole
Neuroleptics
Neurology
Neuropharmacology
Pharmacology. Drug treatments
plasma concentration
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopathology. Psychiatry
Psychopharmacology
Schizophrenia
Serotonin S2 receptors
Title The relationship between the plasma concentration of blonanserin, and its plasma anti-serotonin 5-HT2A activity/anti-dopamine D2 activity ratio and drug-induced extrapyramidal symptoms
URI https://api.istex.fr/ark:/67375/WNG-70Q5RF4S-J/fulltext.pdf
https://onlinelibrary.wiley.com/doi/abs/10.1111%2Fj.1440-1819.2011.02311.x
https://www.proquest.com/docview/1028030151
Volume 66
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Bb9MwFLbQDogLsAGiwCYjIU6kxHacNMdpW6kmrYKxid0sO3ZGVJpUSSoNTvyE_aT9Fn4J7yVuWSdOiJuT2E7sfM_5Xvz8mZA3SaS1G2mU2U_TIDIuDlItwiAXLhXAMEKpcTXyyTSenEfHF_LCxz_hWpheH2L9ww0toxuv0cC1ae4YeTcvyVKvxAlUhQ2RTzIRo4z-4ekfJSkhYu97iYDBQ2wG9fy1IqCr2NNXGC6pG-ixvN_qYoOL3ma03Sdp_IjMVo3pI1Fmw2VrhtmPOzqP_6e1j8lDz1zpfg-1bXLPlTvk_omfm39CbgBxtF7F1n0tFtTHgFHgmHQBLH2uaYarJEsv1UurnJpv4AqUaAflO6pLS4u2WWWGl178-nkNF6sW_xpTCUeTM75PcTUGbnrx3mex4PrP4SnoIV9fo91NujptvbyEXEVpAciWwvcIlRRqKGKhRc33-aKt5s1Tcj4-OjuYBH5_iKAAGsdgbBRajDJw75nUMuROJCFgjInM8JAbm1ueJxIYWmqTlIdCo1qf5dyCU5gYNxLPyFZZle45YAEqEXKUMWeTKJY61UA9cxHb0EQsMtGAvO2woBa9BojS9QxD4hKpvkw_qCT8JE_H0Wd1PCB7G2BZFwDXTcKAGg7I6xV6FFgyTs_o0lXLRiHVQwdVsgGJOyysC9_21CJIAwoUokB1KFBX6uPBFFMv_rXgS_IATvM-uO4V2WrrpdsFttWavc6OfgOchCKu
linkProvider Wiley-Blackwell
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3dbtMwGLXQkIAb_tHKzzAS4oqUJI6T5nLaKGWsFYxO7M5yYgeirUmVptLgikfgkXgWnoTzJWlZJ64Qd4liO7ZzPud89udjxp5HgdZ2oElmP46dILGhE2vhOpmwsQDDcKWm3cjjSTg6Dg5O5El3HBDthWn1IdYTbmQZzXhNBk4T0pesvFmY9OJOihNcxeuDUF4NwDvIE9s_-qMlJUTYeV_C8VCNzbCev5YEwkp9fU4Bk3qBPsvawy422OhFTtv8lIa32NmqOW0syml_WSf99Nslpcf_1N7b7GZHXvlui7Y77Iot7rJr4255_h77CdDxahVe9yWf8y4MjINm8jmI-kzzlDZKFp1aLy8znpzBGyjIFIqXXBeG5_VilRjfPf_1_QceljVNHHOJu9HU3-W0IYPOvXjVJTHw_meoBd_3189485KmTFMtPyNVXhhg2XD8kkhMoUIWgxYtvs7mdTlb3GfHw9fTvZHTHRHh5GByHoZHocUghYfvSS1d34rIBcw8kSa-6ycmM34WSZC02ESx7wpNgn3G9w38wiixA_GAbRVlYbcBBhQi5CD1rImAHx1rsM9MhMZNAi9Igh570YBBzVsZEKWrU4qKi6T6NHmjIveDPBoGH9VBj-1soGWdAd6bxJjq9tizFXwUjJlWaHRhy-VCEdsjH1V6PRY2YFhnvuisBbgGChShQDUoUOfq_d6Erh7-a8an7PpoOj5Uh28n7x6xG0jit7F2j9lWXS3tE5CvOtlpjOo3urAmzQ
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3LbtQwFLVQkSo2vBEDtBgJsSJD4kcyWVYtw1DoqJRWdGfZsQPRMEmUZKTSFZ_AJ_Et_ZLem2SGTsUKsUvkR-zkXPvc-PqYkJeR0NqNNMrsx7EnjAu9WHPfS7mLOTAMX2rcjXwwDScnYv9UnvbxT7gXptOHWP1wQ8tox2s08NKm14y8XZcM4l6JE6hKMAQ-eVOEQCyQIB39kZLiPOydL-4F0Ir1qJ6_1gR8FV_1GcZL6hpeWdqddbFGRq9S2nZOGt8hs2VvulCU2XDRmGFyfk3o8f909y653VNXutNh7R654fL7ZPOgX5x_QH4D5Gi1DK77lpW0DwKjQDJpCTR9rmmC2yTzXquXFik138EXyNEQ8tdU55ZmTb3MDF89u_j5CxKLBn8bUwl3k2O2Q3E7Bp568abPYsH3n0Mr6B5bpdH2IW2dtlp8hVxZbgHJlsKEhFIKFRSx0KP6x7xsinn9kJyM3x7vTrz-gAgvAx4XwODINR8l4N8HUkufOR75ALKAJ4b5zNjUsjSSQNFiG8XM5xrl-ixjFrzCyLgRf0Q28iJ3jwELUAmXoyRwNhKh1LEG7pny0PpGBMKIAXnVYkGVnQiI0tUMY-Iiqb5M36nI_ySPxuKz2h-Q7TWwrAqA7yZhRPUH5MUSPQpMGddndO6KRa2Q66GHKoMBCVssrApfddUEXAMKFKJAtShQZ-pwd4pXT_614HOyebg3Vh_fTz88JbcgB-sC7Z6RjaZauC1gXo3Zbk3qEiutJXw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+relationship+between+the+plasma+concentration+of+blonanserin%2C+and+its+plasma+anti-serotonin+5-HT2A+activity%2F+anti-dopamine+D2+activity+ratio+and+drug-induced+extrapyramidal+symptoms&rft.jtitle=Psychiatry+and+clinical+neurosciences&rft.au=SUZUKI%2C+Hidenobu&rft.au=GEN%2C+Keishi&rft.date=2012-03-01&rft.pub=Wiley-Blackwell&rft.issn=1323-1316&rft.eissn=1440-1819&rft.volume=66&rft.issue=2&rft.spage=146&rft.epage=152&rft_id=info:doi/10.1111%2Fj.1440-1819.2011.02311.x&rft.externalDBID=n%2Fa&rft.externalDocID=25550300
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1323-1316&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1323-1316&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1323-1316&client=summon